Patients with HR+, HER2- metastatic breast cancer whose disease progressed on endocrine therapy (ET) and a CDK4/6 inhibitor have better progression-free survival if they switch ET and receive ribociclib than if they switch ET alone, a phase 2 study suggests.
Researchers sought to determine whether CAR-T therapy would be a viable option for patients with relapsed/refractory large B-cell lymphoma.
Researchers sought to determine whether combining nivolumab plus brentuximab vedotin would improve response rates in CAYAs with Hodgkin lymphoma.
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
US counties with food deserts or food swamps tend to have higher rates of death from obesity-related cancers, a study suggests.
Higher levels of certain sex hormones are associated with an increased risk of some gastrointestinal cancers, a meta-analysis suggests.
Blood type may impact immunotherapy outcomes in patients with metastatic RCC, a study suggests.
Interrupting adjuvant endocrine therapy to attempt pregnancy does not increase the risk of breast cancer recurrence, a study suggests.
Nonalcoholic fatty liver disease is associated with an increased risk of young-onset digestive tract cancers, a study suggests.
Adding tislelizumab to platinum-based chemotherapy improves outcomes in patients with treatment-naïve, advanced esophageal cancer, a phase 3 study suggests.
